JARDIANCE DUO®
JARDIANCE DUO® Film-Coated Tablets
JARDIANCE DUO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who have inadequate glycemic control on metformin or empagliflozin alone, or who are already treated with both empagliflozin and metformin and stabilized. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.1
Overview
Product overview
JARDIANCE DUO® combines 2 antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a member of the biguanide class.1 JARDIANCE DUO® is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.1
Product key facts
Indication
- JARDIANCE DUO® is indicated to improve glycemic control in adults with type 2 diabetes mellitus.1
- Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.1
Active ingredients
- Empagliflozin1
- Metformin1
Legal category
Prescription only medicine
Dosage form and drug content
JARDIANCE DUO® 5/500 mg Film-Coated Tablets1
JARDIANCE DUO® 5/850 mg Film-Coated Tablets1
JARDIANCE DUO® 5/1000 mg Film-Coated Tablets1
JARDIANCE DUO® 12.5/500 mg Film-Coated Tablets1
JARDIANCE DUO® 12.5/850 mg Film-Coated Tablets1
JARDIANCE DUO® 12.5/1000 mg Film-Coated Tablets1
Administration form
Oral administration
Supply packs
4-1000 tablets in PCTFE blister of paper box.1
| Tablet strength | Film-coated tablet, color/shape | Tablet markings | Package size |
|---|---|---|---|
| 5 mg/500 mg | orange yellow, oval, biconvex | Boehringer Ingelheim company symbol and “S5” debossed on one side; the other side is debossed with “500” | 4-1000 tablets in PCTFE blister of paper box. |
| 5 mg/850 mg | yellowish white, oval, biconvex | Boehringer Ingelheim company symbol and “S5” debossed on one side; the other side is debossed with “850” | 4-1000 tablets in PCTFE blister of paper box. |
| 5 mg/1000 mg | brownish yellow, oval, biconvex | Boehringer Ingelheim company symbol and “S5” debossed on one side; the other side is debossed with “1000” | 4-1000 tablets in PCTFE blister of paper box. |
| 12.5 mg/500 mg | pale brownish purple, oval, biconvex | Boehringer Ingelheim company symbol and “S12” debossed on one side; the other side is debossed with “500” | 4-1000 tablets in PCTFE blister of paper box. |
| 12.5 mg/850 mg | pinkish white, oval, biconvex | Boehringer Ingelheim company symbol and “S12” debossed on one side; the other side is debossed with “850” | 4-1000 tablets in PCTFE blister of paper box. |
| 12.5 mg/1000 mg | dark brownish purple, oval, biconvex | Boehringer Ingelheim company symbol and “S12” debossed on one side; the other side is debossed with “1000” | 4-1000 tablets in PCTFE blister of paper box. |
Taiwan NHIA reimbursement criteria
JARDIANCE DUO® is reimbursed under following conditions:
- When JARDIANCE DUO® is used in type 2 diabetes mellitus patients with inadequate glycemic control despite receiving treatment with maximum tolerated dose of metformin.2
- JARDIANCE DUO® should not be used concurrently with single-agent SGLT2 inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and fixed-dose combination containing DPP-4 inhibitors.2
- Do not exceed two tablets per day.2
- Prescription of oral antidiabetic drugs (OAD) should not exceed four ingredients for type 2 diabetes mellitus.2
Footnotes:
-
DPP-4, dipeptidyl peptidase-4; NHIA, National Health Insurance Administration; SGLT2, sodium-glucose co-transporter 2; OAD, oral antidiabetic drugs.
References:
-
JARDIANCE DUO® approved package insert. Updated in December 2020 and approved in June 2021.
-
Taiwan National Health Insurance Administration. Reimbursement criteria for hormones and drugs affecting hormonal mechanism http://www.e-ms.com.tw/subweb/pharmacy/education/chap5.pdf Accessed 30 Oct 2021.